Novel chemoenzymatic protocol for the synthesis of 3′-O- dimethoxytrityl-2′-deoxynucleoside derivatives as building blocks for oligonucleotide synthesis

Organic Process Research and Development

Volumn 10, Issue 3, 2006, Pages 581-587

  Díaz Rodríguez, Alba ^a   Fernández, Susana ^a   Sanghvi, Yogesh S ^b   Ferrero, Miguel ^a   Gotor, Vicente ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b RASAYAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745745838     PISSN: 10836160     EISSN: None     Source Type: Journal    
DOI: 10.1021/op050253i     Document Type: Article

References (44)

1. (a) Crooke, S. T., Ed. Antisense Drug Technology Principles, Stategies and Applications; Marcel Dekker: New York, 2001.
2. (b) Sanghvi, Y. S. In Comprehensive Natural Products Chemistry; Kool, E. T., Ed.; Elsevier: Amsterdam, 1999; Vol. 7, Chapter 7, pp 285-311 and references therein.
3. ISIS Pharmaceuticals (www.isispharm.com) has the largest portfolio of antisense oligonucleotide products currently in clinical trials.
4. (a) For a recent review of oligo- and poly-nucleotide synthesis, see; Reese, C. B. Org. Biomol. Chem. 2005, 3, 3851-3868.
5. (b) Sanghvi, Y. S.; Andrade, M.; Deshmukh, R. R.; Holmberg, L.; Scozzari, A. N.; Cole, D. L. In Manual of Antisense Methodology; Hartmann, G.; Endres, S., Eds.; Kluwer Academic Publishers: Hingham, 1999; pp 3-23.
6. (a) Gukathasan, R.; Massoudipour, M.; Gupta, I.; Chowdhury, A.; Pulst, S.; Sivakumar, R.; Sanghvi, Y. S.; Laneman, S. J. Organomet. Chem. 2005, 690, 2603-2607.
7. (b) Wang, Z.; Cedillo, I.; Cole, D. L.; Sanghvi, Y. S.; Hinz, M.; Prukala, W.; Sobkowski, M.; Seliger, H.; Rimmler, M.; Ditz, R.; Hoffmeyer, J. In Innovation and Perspectives in Solid-Phase Synthesis & Combinatorial Libraries; Epton, R., Ed.; Mayflower Worldwide Ltd.: England, 2004; pp 118-122.
8. (c) Sanghvi, Y. S.; Guo, Z.; Pfundheller, H. M.; Converso, A. Org. Process Res. Dev. 2000, 4, 175-181.
9. (d) Pon, R. T.; Yu, S.; Guo, Z.; Sanghvi, Y. S. Nucleic Acid Res. 1999, 27, 1531-1538.
10. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis; 3rd ed.; Wiley: New York, 1999.
11. (a) Klibanov, A. M. Nature 2001, 409, 241-246.
12. (b) Koeller, K. M.; Wong, C.-H. Nature 2001, 409, 232-240.
13. (c) Patel, R. N. Stereoselective Biocatalysis; Marcel Dekker: New York, 2000.
14. (d) Carrea, G.; Riva, S. Angew. Chem. Int. Ed. 2000, 39, 2226-2254.
15. (e) Bornscheuer, U. T.; Kazlauskas, R. J. Hydrolases in Organic Synthesis. Regio- and Stereoselective Biotransformations; Wiley-VCH: Weinheim, 1999.
16. For reviews on enzymatic transformations in nucleosides, see: (a) Ferrero, M.; Gotor, V. Chem. Rev. 2000, 100, 4319-4347.
17. (b) Ferrero, M.; Gotor, V. Monatsh. Chem. 2000, 131, 585-616.
18. (a) Lavandera, I.; García, J.; Fernández, S.; Ferrero, M.; Gotor, V.; Sanghvi, Y. S. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley and Sons: New York, 2005; Chapter 2.11.
19. (b) García, J.; Fernández, S.; Ferrero, M.; Sanghvi, Y. S.; Gotor, V. Org. Lett. 2004, 6, 3759-3762.
20. (c) García, J.; Fernández, S.; Ferrero, M.; Sanghvi, Y. S.; Gotor, V. Tetrahedron: Asymmetry 2003, 14, 3533-3540.
21. (d) García, J.; Fernández, S.; Ferrero, M.; Sanghvi, Y. S.; Gotor, V. J. Org. Chem. 2002, 67, 4513-4519.
22. García, J.; Fernández, S.; Ferrero, M.; Sanghvi, Y. S.; Gotor, V. Tetrahedron Lett. 2004, 45, 1709-1712.
23. (a) Chattopadhyaya, J. B.; Reese, C. B. J. Chem. Soc., Chem. Commun. 1978, 639-640.
24. (b) Bamett, W. E.; Needham, L. L.; Powell, R. W. Tetrahedron 1972, 28, 419-424.
25. (a) McGee, D. P. C.; Martin, J. C.; Webb, A. S. Synthesis 1983, 540-541.
26. (b) Ti, G. S.; Gaffney, B. L.; Jones, R. A. J. Am. Chem. Soc. 1982, 104, 1316-1319.
27. (c) Schaller, H.; Weiman, G.; Lerch, B.; Khorana, H. G. J. Am. Chem. Soc. 1963, 85, 3821-3827.
28. Reddy, M. P.; Rampal, J. B.; Beaucage, S. L. Tetrahedron Lett. 1987, 28, 23-26.
29. (a) D'Onofrio, J.; Montesarchio, D.; De Napoli, L.; Di Fabio, G. Org. Lett. 2005, 7, 4927-4930.
30. (b) Wagner, T.; Pfleiderer, W. Helv. Chim. Acta 2000, 83, 2023-2035.
31. (c) Esipov, D. S.; Esipova, O. V.; Korobko, V. G. Nucleosides Nucleotides 1998, 17, 1697-1704.
32. (d) Robles, J.; Pedroso, E.; Grandas, A. Nucleic Acids Res. 1995, 23, 4151-4161.
33. Macugen is developed and marketed by Eyetech Pharmaceutical, Inc. and Pfizer, Inc.
34. Nimjee S. M.; Rusconi C. P.; Sullenger B. A. Annu. Rev. Med. 2005, 56, 555-583.
35. Wang, G.; Seifert, W. E. Tetrahedron Lett. 1996, 37, 6515-6518.
36. Sekine, M.; Hata, T. J. Org. Chem. 1983, 48, 3011-3014.
37. (a) Eleuteri, A.; Cheruvallath, Z. S.; Capaldi, D. C.; Cole, D. L.; Ravikumar, V. T. Nucleosides Nucleotides 1999, 18, 1803-1807.
38. (b) Krotz, A. H.; Klopchin, P.; Cole, D. L.; Ravikumar, V. T. Nucleosides Nucleotides 1997, 16, 1637-1640.
39. (c) Iwai, S.; Toshiro, S.; Ohtsuka, E. Tetrahedron 1990, 46, 6673-6688.
40. (a) Kumar, G.; Celewicz, L.; Chládek, S. J. Org. Chem. 1982, 47, 633-644.
41. (b) van Boom, J. H.; Burguess, P. M. J.; Verdegaal, C. H. M.; Wille, G. Tetrahedron 1978, 34, 1999-2007.
42. Pedersen, D. S.; Rosenbohm, C. Synthesis 2001, 2431-2434.
43. (a) Sanghvi, Y. S.; Ravikumar, V. T.; Scozzari, A. N.; Cole, D. L. Pure Appl. Chem. 2001, 73, 175-180.
44. (b) Green Chemical Syntheses and Processes; Anastas, P. T.; Heine, L. G.; Williamson, T. C., Eds.; ACS Symposium Series 767; American Chemical Society: Washington, DC, 2000.